Shenzhen Hepalink Schedules Board Meeting to Review Q3 Results
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for October 30, 2025, to review its Q3 results for the period ending September 30, 2025. This meeting is crucial for understanding the company's financial performance and strategic direction. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector, focusing on heparin products and related services, with a current market cap of HK$17.23B.
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced a board meeting scheduled for October 30, 2025, to review and approve the company’s third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development and manufacturing of heparin products and other related pharmaceutical services.
Average Trading Volume: 2,697,658
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.23B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.
